We aimed to assess the impact of ophthalmology weight-based hydroxychloroquine (HCQ) dosing guidelines on prescribing patterns. We examined initial HCQ prescription dosing between 2007 and 2016 and determined independent predictors for HCQ dosing above the previous (2011) recommended ≤ 6.5 mg/kg of ideal body weight (IBW)/day and the latest (2016) recommended ≤ 5.0 mg/kg of actual body weight (ABW)/day using logistic regression. Among 17,797 patients (82% female), the proportion of 400 mg prescribed daily dosing declined sharply from 80% in 2007-2011 to nearly 40% in 2014, whereas the proportions of 200-and 300-mg daily doses showed the opposite trends during the same periods. Accordingly, the risk of HCQ dosing above the guideline recommendations declined by more than 60%. While 36% of normal body mass index (BMI) individuals were classified as dosing above the IBW-based guideline, 66% would have received dosing above the latest ABW-based guideline. The risk of excess dosing was associated with female patients and dermatology prescribers (adjusted odds ratios ≥ 2 according to IBW-or ABW-based guidelines). There has been a sharp decline in HCQ dosing following ophthalmology weight-based guidelines in recent years. While this trend is likely helpful in reducing the risk of retinopathy, its potential impact on HCQ efficacy remains to be clarified.
Introduction
Hydroxychloroquine (HCQ) is widely used in the treatment of systemic lupus erythematosus (SLE), with benefits including improved survival, reduced disease activity, and a lower risk of pregnancy complications, venous thromboembolism, dyslipidemia, and insulin resistance [1] [2] [3] [4] [5] [6] [7] . HCQ is also commonly used as a component of Btriple therapy^in the treatment of rheumatoid arthritis (RA) and in other autoimmune and dermatologic conditions [8] .
The major long-term risk of this otherwise well tolerated medication is vision-threatening retinopathy [9, 10] . Historically, HCQ retinopathy was considered to be rare [11] [12] [13] , but a recent study in Kaiser Permanente Northern California (KPNC) using more sensitive screening methods showed a prevalence of 7.5% among long-term HCQ users and reinforced earlier reports that daily dose is a key risk factor in the development of toxicity [14] . To reduce the risk of retinopathy, the 2011 American Academy of Ophthalmology (AAO) guidelines recommended a maximum safe dose of 6.5 mg/kg/day (as determined by ideal body weight [IBW] ) [15] . However, after the recent KPNC study suggested that actual body weight (ABW) was a better predictor of HCQ retinopathy than IBW [14] , the AAO updated its guidelines in 2016 to recommend a maximum daily dose of 5.0 mg/kg/day by ABW [16] . As these guidelines were developed by ophthalmologists, who are not typical prescribers of HCQ, it remains largely unknown to what extent these guidelines have impacted HCQ prescribing patterns in the USA.
To examine the impact of ophthalmology weight-based HCQ dosing guidelines on prescribing patterns, we assessed HCQ prescriptions over a recent 10-year period among 17,797 HCQ initiators from a US large population-based cohort.
Materials and methods

Data source
Our study data source was KPNC, a large integrated health network which includes a diverse population of approximately 4.1 million patients. The KPNC electronic medical record database includes demographic and pharmacy data for all patients in the KPNC service area. Health care information includes demographics, outpatient and inpatient encounters, practitioner specialty, diagnoses, medication dispensing, imaging, and laboratory results.
Study population and design
We identified subjects age 21 or older with at least 1 or more prior years of KPNC membership with incident HCQ prescriptions between January 1, 2007 and December 31, 2016. Prescriptions for an indication of malaria prophylaxis were excluded. We divided the 10-year study period into five 2-year cohorts based on the date of the first HCQ prescription to examine the prescription trends.
Assessment of HCQ prescriptions
We determined the incident HCQ prescription doses based on the Sig instructions in the medication order. For prescriptions written for initial dose uptitration or a loading dose, we included the intended ongoing prescription dose in the analysis. We classified the weight-based HCQ dose according to the AAO recommended maximum dose per IBW (i.e., > 6.5 mg/kg/day) and ABW (i.e., > 5.0 mg/kg/day) [15, 16] .
Assessment of covariates
Covariate information was derived from the most recent available data within 1 year of the index HCQ prescription date for demographic (i.e., age, sex) and anthropometric (i.e., height, weight) characteristics. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. IBW was calculated by the Devine formula: for women, IBW = 45.5 + 2.3 kg for each inch of height over 60 in. and for men, IBW = 50 + 2.3 kg for each inch of height over 60 in. [17] . Patients without a recorded height or a height under 60 in. were excluded from the IBW-related analyses (n = 697). Other covariates of interest were prescriber specialty, chronic kidney disease (CKD; stage ≥ 3), and indication for HCQ therapy.
Statistical analysis
We compared the baseline characteristics of individuals at the index date of their incident HCQ prescriptions according to calendar year categories. We calculated the proportion of different HCQ doses and categorized them into the nearest 100 mg (one half tablet) daily dose (i.e., 200, 300 mg, 400, and over 400 mg) over each of the five 2-year cohorts over the study period. The proportion of incident HCQ prescriptions above the prior IBW-based recommended maximum daily dose [15] or the latest ABW-based recommended maximum daily dose [16] was calculated over the study period. We examined the trends of median and interquartile ranges for initial HCQ dose per IBW and ABW between 2007 and 2016 using quantile regression. We also examined the relation of age, sex, BMI, CKD, provider specialty, and indication for HCQ use to the risk of prescribed HCQ dose above the IBW-or ABWbased recommended dose using logistic regression. The final multivariable model was adjusted for age, sex, BMI, CKD, prescriber specialty, and calendar year.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request and with permission from Kaiser Permanente Northern California Division of Research.
Results
During the 10-year period between 2007 and 2016, 17 ,797 individuals initiated HCQ therapy ( Table 1 ). The majority were female (82%) with a mean age of 53.2 years and a mean BMI of 28.4 kg/m 2 . Rheumatologists were the most common prescribers of HCQ (69%), followed by primary care providers (18%) and dermatologists (9%). RA was the most common indication for HCQ use (46%), followed by dermatologic conditions (18%), SLE (15%), and other systemic autoimmune conditions (15%). Dermatologic conditions included cutaneous lupus (together, discoid and subacute cutaneous lupus comprised 33%), as well as alopecia, lichen planus, dermatitis, granuloma annulare, psoriasis, and urticaria. One thousand four hundred and fifty-two (8.2%) prescriptions were written with an initial low starting dose with instructions to raise the dose as tolerated by patient, and 330 (1.9%) were written with an initial loading dose.
During the study period, the proportion of 400 mg prescribed daily dosing declined sharply from 80% in 2011 to nearly 40% in 2014 ( (Table 2) . Using the IBW-based recommendation, 50% of women and 7% of men had dosing over 6.5 mg/kg, with an adjusted OR of 17.91 (95% CI, 15.51-20.67) for women ( Table 2) . Using the ABW-based recommendation, women also had a higher proportion (44%) of initial prescription dosing over BMI had opposite effects on the proportions of excess prescribing by IBW-versus ABW-based dosing. Proportions of initial HCQ dosing above the IBW-based recommendation increased with higher BMI (22, 36, 42 , and 49% in underweight, normal, overweight, and obese categories, respectively) ( 
Discussion
In this population-based cohort from a large integrated health plan, we found that the daily dose for new HCQ prescriptions declined considerably starting in 2011, coinciding with the Two previous, small-scale, single-center studies (n = 554 and n = 1681) have reported conflicting findings of HCQ dosing trends [18, 19] . The first study captured all rheumatology patients (n = 554) who initiated HCQ between 2009 and 2016 and were seen by an ophthalmologist in a university health care system and reported no change in HCQ trend [19] . While this may reflect the local practice pattern, it is also conceivable that the requirement to be seen by an ophthalmologist may have selected patients with higher initial dosing more frequently even in the recent years. In contrast, another university center study captured all patients (n = 1681) who received any HCQ prescription between 2012 and 2016 and reported a substantial decline in excess dosing, similar to ours [18] . Our study is over ten times larger than this study and spans twice its duration, and we were able to address initial dosing trends.
The vision-threatening nature of HCQ retinopathy likely explains the fast guideline adoption by prescribers. In contrast, concerns regarding patient non-adherence to HCQ, as seen in up to half of all patients with SLE [14, 20] , may prevent some providers from lowering the prescription dose of this important medication. To that end, it remains to be clarified whether the renewed concern about HCQ retinopathy may worsen HCQ compliance. While the dosing trend may reduce the risk of retinopathy, its potential impact on HCQ's wide-ranging benefits (particularly in SLE) remains a concern. To that effect, the recent increase in dosing (2015-2016) is intriguing, as it might indicate a response by prescribers to a loss of clinical efficacy at lower doses of HCQ. Further studies are needed to clarify whether reducing HCQ dose, per the ophthalmology guidelines, will retain efficacy for the treatment of SLE and other rheumatic diseases. Such data would enable us to assess the net benefit of the observed HCQ dosing trend. In terms of patient factors associated with a higher risk of HCQ dosing above the weight-based recommendations, we found that excess dosing was more prominent among women, occurring in a large proportion (i.e., 50% of women using the IBW criteria and 44% using the ABW criteria). This is explained in part because women are shorter on average and height is included in the IBW calculation, systematically leading to a lower IBW among women; women also have a lower average ABW than men. Therefore, the commonly prescribed HCQ dose of 400 mg daily exceeds the recommended maximum daily dose range according to both 2011 IBW-based and 2016 ABW-based guidelines for the average US female [21] .
Dermatologists showed a higher risk of excess HCQ dosing (50%) compared with rheumatologists (40%) and primary care physicians (41%). This may suggest potential differences in awareness of AAO dosing guidelines or perception of the risk of toxic retinopathy among specialties. Alternatively, this could indicate higher treatment doses used for some cutaneous indications despite discordance with the ophthalmology dosing guidelines, as two prospective studies found greater efficacy in treating cutaneous lupus with HCQ dosing > 5 mg/kg/ day ABW [22, 23] . The presence of concomitant CKD was associated with a reduced risk of HCQ excess dosing, which reflects HCQ dose adjustment in patients with renal disease. Although there has not been a clear consensus on appropriate dose reduction in renal insufficiency [24] , CKD has been associated with a more than twofold increase of the prevalence of HCQ retinopathy [14] . Nevertheless, more than 30% of CKD patients' prescriptions still exceeded the recommended doses by either guideline, suggesting potential room for improvement even in this subpopulation.
BMI categories posed opposing risks of excess dosing between the two weight-based dosing guidelines. While 36% of normal BMI individuals were exposed to dosing above the IBW-based guidelines, 66% would have been exposed to dosing above the latest ABW-based guidelines. In contrast, 44% of obese individuals were exposed to dosing above the IBWbased guideline, compared with only 9% using the ABWbased guideline. While the latest evidence, based on a sample of nearly 2500 long-term HCQ users, suggests that ABWbased dosing is a better predictor of toxicity [14] , confirming these findings in a prospective study would be valuable. In the meantime, some authors advocate using the lower of the two methods to minimize retinopathy risk [25] . Nevertheless, the impact of IBW-or ABW-based dosing treatment efficacy of HCQ remains unknown, calling for future investigations.
Our study has several strengths and limitations which warrant recognition. Our source population KPNC is generally representative of the residents of that region [26] . As such, our study captured a diverse patient population as well as prescription dosing by multiple providers and provider specialties and provides population-level data on HCQ prescribing patterns in relation to HCQ dosing guidelines. Furthermore, our study was substantially longer and larger than previous single-center studies, providing higher precision in our results [18, 19] . However, our data lacked information regarding disease activity for patients with SLE, RA, and other conditions, limiting our ability to assess its potential relationship with initial HCQ dosing. It would be valuable for future studies to address this issue.
In conclusion, in this large population-based cohort, we found that there has been a sharp decline in HCQ dosing, corresponding with 2011 AAO guidelines on weight-based HCQ dosing. While this trend is likely helpful in reducing the risk of retinopathy, its potential impact on HCQ's antirheumatic efficacy remains to be clarified to allow assessment of the net impact of this dramatic dosing trend.
